Telmisartan lowers elevated blood pressure in psoriatic mice without attenuating vascular dysfunction and inflammation

  • Background: Psoriasis is hallmarked by vascular dysfunction, arterial hypertension, and an increased risk for cardiovascular diseases. We have shown recently that skin-driven interleukin (IL)-17A expression promotes psoriasis-like disease in mice, and this is associated with vascular inflammation, vascular dysfunction, and hypertension. As an intensive risk-factor reduction is recommended for psoriasis patients, we aimed to elucidate the impact of the angiotensin II receptor type 1 (AT1) antagonist telmisartan in a mouse model of severe psoriasis-like skin disease. Methods and Results: Elevated blood pressure measured by tail-cuff plethysmography in mice with keratinocyte-specific IL-17A overexpression (K14-IL-17Aind/+ mice) was significantly reduced in response to telmisartan. Importantly, vascular dysfunction, as assessed by isometric tension studies of isolated aortic rings, vascular inflammation measured by flow cytometry analysis of CD45+CD11b+ immune cells, as well as the increased peripheral oxidative stress levels assessed by L-012-enhanced chemiluminescence were not attenuated by telmisartan treatment of K14-IL-17Aind/+ mice, nor was the persisting skin inflammation. Conclusion: We provide first evidence for an effective antihypertensive treatment in experimental psoriasis by AT1 blockade, but without any impact on vascular inflammation and dysfunction in our mouse model of severe psoriasis-like skin disease. This suggests that vascular function and inflammation in psoriasis might not be attenuated as long as skin inflammation persists.

Download full text files

Export metadata

Metadaten
Author:Johannes Wild, Rebecca Schüler, Tanja KnoppORCiD, Michael Molitor, Sabine KossmannORCiDGND, Thomas MünzelORCiDGND, Andreas DaiberORCiDGND, Ari WaismanORCiDGND, Philip WenzelORCiDGND, Susanne Helena KarbachORCiDGND
URN:urn:nbn:de:hebis:30:3-529795
DOI:https://doi.org/10.3390/ijms20174261
ISSN:1422-0067
ISSN:1661-6596
Pubmed Id:https://pubmed.ncbi.nlm.nih.gov/31480330
Parent Title (English):International journal of molecular sciences
Publisher:Molecular Diversity Preservation International
Place of publication:Basel
Document Type:Article
Language:English
Year of Completion:2019
Date of first Publication:2019/08/30
Publishing Institution:Universitätsbibliothek Johann Christian Senckenberg
Release Date:2020/03/02
Tag:Interleukin-17A; hypertension and anti-hypertensive treatment; psoriasis; telmisartan; vascular dysfunction and inflammation
Volume:20
Issue:17, Art. 4261
Page Number:10
First Page:1
Last Page:10
Note:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
HeBIS-PPN:460971190
Institutes:Medizin / Medizin
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Sammlungen:Universitätspublikationen
Licence (German):License LogoCreative Commons - Namensnennung 4.0